Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment

Abstract

BackgroundAberrant patterns of DNA methylation are abundant in cancer, and epigenetic pathways are increasingly being targeted in cancer drug treatment. Genetic components of the folate-mediated one-carbon metabolism pathway can affect DNA methylation and other vital cell functions, including DNA synthesis, amino acid biosynthesis, and cell growth.ResultsWe used a bioinformatics tool, the Transcriptional Pharmacology Workbench, to analyze temporal changes in gene expression among epigenetic regulators of DNA methylation and demethylation, and one-carbon metabolism genes in response to cancer drug treatment. We analyzed gene expression information from the NCI-60 cancer cell line panel after treatment with five antitumor agents, 5-azacytidine, doxorubicin, vorinostat, paclitaxel, and cisplatin. Each antitumor agent elicited concerted changes in gene expression of multiple pathway components across the cell lines. Expression changes of FOLR2, SMUG1, GART, GADD45A, MBD1, MTR, MTHFD1, and CTH were significantly correlated with chemosensitivity to some of the agents. Among many genes with concerted expression response to individual antitumor agents were genes encoding DNA methyltransferases DNMT1, DNMT3A, and DNMT3B, epigenetic and DNA repair factors MGMT, GADD45A, and MBD1, and one-carbon metabolism pathway members MTHFD1, TYMS, DHFR, MTR, MAT2A, SLC19A1, ATIC, and GART.ConclusionsThese transcriptional changes are likely to influence vital cellular functions of DNA methylation and demethylation, cellular growth, DNA biosynthesis, and DNA repair, and some of them may contribute to cytotoxic and apoptotic action of the drugs. This concerted molecular response was observed in a time-dependent manner, which may provide future guidelines for temporal selection of genetic drug targets for combination drug therapy treatment regimens.Electronic supplementary materialThe online version of this article (doi:10.1186/s13148-016-0240-3) contains supplementary material, which is available to authorized users.

Single nanomolar doxorubicin exposure triggers compensatory mitochondrial responses in H9c2 cardiomyoblasts

“…Shock et al reported not only the presence of 5mC and 5hmC in mammalian mtDNA, but also a mitochondrial DNMT1 that binds to the mtDNA and regulates the expression of particular mitochondrial genes (Shock et al, 2011). Interestingly, we observed a decrease in DNMT1 mRNA levels after DOX treatment, which was similar to previous reports (Krushkal et al, 2016;Yokochi and Robertson, 2004). This DNMT1 down-regulation was most pronounced at day 0, right after the exposure to DOX, and resolved over time.…”

Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism

“…The global DNA methylation status is influenced by several factors, including dietary intake of enzymatic cofactors such as B9 (folate), B12 and B6 vitamins. Such cofactors play a key role in MTHFR-mediated onecarbon metabolic pathway, thus impacting overall DNA methylation levels [46]. Genotype analysis of our rGBM patients' cohort showed that 62% of patients had at least one mutated allele for the rs1801133MTHFR gene polymorphism (CT = 49%; TT = 13%).…”

A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma

“…Thus, the potential synergy between ADI-PEG20 and autophagy inhibitors warrants further clinical investigation. At disease progression, he underwent debulking surgery where the histology reconfirmed glioblastoma and molecular analysis showed no mutations in IDH1/2, although interestingly MGMT promoter methylation was now present at a low level (>0-5%) and may reflect prior treatment with cisplatin (32). Intriguingly, his recurrent tumor on ADI-PEG20 monotherapy remained ASS1deficient ( Supplementary Fig.…”